02496.HK
Wuhan YZY Biopharma Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 3.80
+0.00%Margins
Gross margin
16.3%
EBITDA margin
-105.3%
EBIT margin
-116.9%
Net margin
-114.7%
FCF margin
-48.6%
183.3%
Return on equity
-55.5%
Return on assets
-132.5%
Return on invested capital
0.48x
Asset turnover
-HKD 47.1M
Cash from operations
HKD 0.61
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Dec 1, 2025